Compare MPB & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | PLRX |
|---|---|---|
| Founded | 1868 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 74.9M |
| IPO Year | 1996 | 2020 |
| Metric | MPB | PLRX |
|---|---|---|
| Price | $34.33 | $1.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $37.00 | $2.67 |
| AVG Volume (30 Days) | 111.6K | ★ 537.0K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | $94.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.21 | $1.09 |
| 52 Week High | $35.22 | $1.95 |
| Indicator | MPB | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.38 | 45.21 |
| Support Level | $30.82 | $1.13 |
| Resistance Level | $34.88 | $1.37 |
| Average True Range (ATR) | 0.77 | 0.05 |
| MACD | 0.23 | -0.00 |
| Stochastic Oscillator | 96.96 | 24.14 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.